Cogent Biosciences宣布，美国食品药品监督管理局（FDA）已正式受理其新药Bezuclastinib用于治疗非晚期系统性肥大细胞增多症（Nonadvsm）的新药申请。这一重要进展标志着该药物在监管审批流程中迈出了关键一步，为非晚期系统性肥大细胞增多症患者带来了新的治疗希望。
Cogent Biosciences宣布，美国食品药品监督管理局（FDA）已正式受理其新药Bezuclastinib用于治疗非晚期系统性肥大细胞增多症（Nonadvsm）的新药申请。这一重要进展标志着该药物在监管审批流程中迈出了关键一步，为非晚期系统性肥大细胞增多症患者带来了新的治疗希望。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.